Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating) – Analysts at Oppenheimer issued their FY2027 earnings per share estimates for shares of Orchard Therapeutics in a research report issued on Monday, March 13th. Oppenheimer analyst H. Singh expects that the company will earn ($0.62) per share for the year. The consensus estimate for Orchard Therapeutics’ current full-year earnings is ($16.13) per share.
Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Orchard Therapeutics in a report on Tuesday, November 15th.
Orchard Therapeutics Price Performance
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the business. Federated Hermes Inc. increased its holdings in shares of Orchard Therapeutics by 1.1% in the 3rd quarter. Federated Hermes Inc. now owns 8,401,687 shares of the company’s stock valued at $4,201,000 after acquiring an additional 91,828 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Orchard Therapeutics by 27.6% in the 3rd quarter. Renaissance Technologies LLC now owns 2,535,439 shares of the company’s stock valued at $1,268,000 after acquiring an additional 549,151 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Orchard Therapeutics by 19.9% in the 1st quarter. BlackRock Inc. now owns 749,990 shares of the company’s stock valued at $534,000 after acquiring an additional 124,478 shares during the last quarter. Mariner LLC acquired a new stake in shares of Orchard Therapeutics in the 4th quarter valued at about $234,000. Finally, Strategic Wealth Advisors Group LLC acquired a new stake in shares of Orchard Therapeutics in the 3rd quarter valued at about $258,000. Hedge funds and other institutional investors own 44.08% of the company’s stock.
Orchard Therapeutics Company Profile
Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies.
- Get a free copy of the StockNews.com research report on Orchard Therapeutics (ORTX)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.